FY 2025
Loading financial data...
|
Chart |
FY21
Dec 31, 2021
|
FY22
Dec 31, 2022
|
FY23
Dec 31, 2023
|
FY24
Dec 31, 2024
|
FY25
Dec 31, 2025
|
TTM
Trailing 12M
|
|---|---|---|---|---|---|---|---|
|
Revenue
Total sales generated. |
|
$16.07 B | $12.17 B | $13.12 B | $14.20 B | $14.34 B | $14.92 B |
|
Cost of Revenue Direct cost of goods/services. |
|
$2.72 B | $1.71 B | $2.24 B | $1.97 B | $1.97 B | $2.31 B |
Gross Profit Revenue minus cost of revenue. |
|
$13.35 B | $10.47 B | $10.87 B | $12.23 B | $12.37 B | $12.61 B |
|
Operating Expense
Costs to run business. 
|
|
$4.40 B | $5.08 B | $6.52 B | $8.24 B | $8.68 B | $8.98 B |
Operating Income Profit from operations. |
|
$8.95 B | $5.39 B | $4.35 B | $3.99 B | $3.69 B | $3.63 B |
|
Net Interest Income
Interest income minus expense.
|
|
-$57.30 M | $100.70 M | $422.90 M | $656.20 M | -$43.80 M | $678.70 M |
Non-Operating Income (ex-Int) Income outside core operations. |
|
-$436.30 M | $467.40 M | $76.30 M | -$844.40 M | -$1.58 B | -$1.58 B |
Total Other Income (Net) Net non-operating items. |
|
$379.00 M | -$526.80 M | -$149.30 M | $789.20 M | $1.54 B | $1.53 B |
Income Before Tax Profit before taxes. |
|
$9.33 B | $4.86 B | $4.20 B | $4.78 B | $5.23 B | $5.16 B |
Income Tax Expense Taxes on income. |
|
$1.25 B | $520.40 M | $245.70 M | $367.30 M | $725.80 M | $733.50 M |
|
Net Income
Final profit.
|
|
$8.08 B | $4.34 B | $3.95 B | $4.41 B | $4.50 B | $4.42 B |
|
Earnings Per Share
Company profit allocated to each outstanding share. |
|||||||
EPS Earnings per share. Formula: Net Income ÷ Shares |
|
$76.40 | $40.51 | $37.05 | $40.90 | $43.07 | $42.53 |
Diluted EPS EPS including dilution. Formula: Net Income ÷ Diluted Shares |
|
$71.97 | $38.22 | $34.77 | $38.34 | $41.48 | $41.04 |
|
Shares for EPS
Number of shares used to calculate EPS. |
|||||||
Weighted Average Shares Outst. Avg shares used for EPS. |
|
105.70 M | 107.10 M | 106.70 M | 107.90 M | 104.60 M | 104.00 M |
Diluted Average Shares Outst. Shares including dilution. |
|
112.20 M | 113.50 M | 113.70 M | 115.10 M | 108.60 M | 107.70 M |
| Supplemental Items | |||||||
EBIT Earnings before interest and tax. |
|
$9.38 B | $4.92 B | $4.27 B | $4.84 B | $5.27 B | $5.20 B |
EBITDA Earnings before interest, tax, D&A. |
|
$9.67 B | $5.26 B | $4.69 B | $5.32 B | $5.27 B | $5.74 B |
Depreciation and Amortization Non-cash expense for assets. |
|
$286.20 M | $341.40 M | $421.00 M | $482.90 M | - | $540.00 M |
| Company Report |
FY 2025
Regeneron Pharmaceuticals's Balance Sheet
-
$ USD
-
€ EUR
-
€ EUR
-
€ EUR
-
-
-
| Loading balance sheet when needed... |
Regeneron Pharmaceuticals's Cash flow
-
$ USD
-
€ EUR
-
€ EUR
-
€ EUR
-
-
-
| Loading cash flow statement when needed... |
Regeneron Pharmaceuticals's Profitability
-
$ USD
-
€ EUR
-
€ EUR
-
€ EUR
-
-
-
| Loading profitability metrics when needed... |
Regeneron Pharmaceuticals's Ratios
-
$ USD
-
€ EUR
-
€ EUR
-
€ EUR
-
-
-
